Long-term double-blind extension study of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps

Double-blind trial of itepekimab in chronic rhinosinusitis with nasal polyps (CRSwNP) (2 arms), sponsored by Sanofi. Primary endpoint: Incidence of treatment-emergent adverse events, adverse events of special interest, serious adverse events, adverse events leading to death, and adverse events leading to permanent treatment… Started Aug 2026; status: completed.